ABBN.SW (ABBN.SW)

$119.4B
Market Cap
33.5
P/E Ratio
0.90
Beta
1.40%
Dividend Yield
Piotroski 7/9Altman Z 4.7 SafeROIC−WACC +7.5%

Quantitative Summary

Deterministic

Financial health metrics are strong: Piotroski 7/9, Altman Z 4.7 (above 3.0 safe zone threshold).

Generated deterministically from quant metrics and financial statements. Not a recommendation.

Algorithmic Teardown

AI-Generated

The capital allocation efficiency of ABBN.SW demonstrates robust fundamental quality, characterized by a 17.5% ROIC that significantly outperforms the estimated cost of equity at 10.0%, generating a +7.5% spread indicative of strong value creation potential. This high return on equity of 28.4% is primarily driven by superior profitability margins rather than operational leverage or balance sheet expansion; specifically, a net margin of 14.2% and gross margin of 41.1% are the dominant contributors, while asset turnover remains moderate at 0.74x with an equity multiplier of 2.70x suggesting conservative financial engineering. Financial stability is further corroborated by a Piotroski F-Score of 7/9 and an Altman Z-Score of 4.7, positioning the firm in the low-risk zone relative to bankruptcy probability while signaling strong operating performance trends over the trailing period.

Valuation metrics present a notable divergence between current market pricing and intrinsic value estimates derived from discounted cash flow analysis. The stock currently trades at a forward P/E multiple of 33.5x, which implies significant growth expectations that must be realized to justify the premium relative to historical norms or sector peers not explicitly detailed here. In contrast, the DCF model calculates a fair value of $84, suggesting that if current revenue growth assumptions hold steady and future cash flows materialize as projected, the market price may carry an implied discount or require re-rating depending on whether the actual trading price falls below this threshold. The gap between these valuation anchors highlights the sensitivity of the stock's attractiveness to investor sentiment regarding its long-term growth trajectory versus immediate multiple compression risks.

Although specific risk factor deltas and insider activity data were not provided in the input, the combination of a high Piotroski score and solid Altman Z-Score suggests limited fundamental distress risks at this juncture. However, the elevated P/E ratio inherently embeds substantial expectations for future performance; any deviation from the implied growth rate required to support such multiples could lead to significant valuation re-pricing. The interplay between the company's ability to maintain its high margin profile and execute on revenue growth will be critical in determining whether current valuations remain sustainable or become a drag on total returns.

Generated by LLM from quantitative data inputs. May contain inaccuracies. Not investment advice.

DCF Sandbox

Interactive

Sensitivity Matrix

TG ↓ / WACC →8%10%12%
2%$103$75$58
3%$122$84$63
4%$149$96$70

Center = base case. Green = >10% upside, Red = >10% downside vs .

Pre-computed DCF: WACC=10.0%, terminal growth 3%. Fair value $84 (+0.0%). Not investment advice.

Price Chart with Moving Averages

Loading chart...
SMA 50 SMA 200

Quant Health Deep Dive

7/9
Piotroski F-Score
Strong — high operational efficiency and profitability signals
4.7
Altman Z-Score
Safe Zone — above 3.0 threshold per academic model. Thresholds: >3 safe, 1.8–3 grey, <1.8 distress.

Profitability & Value Creation

41.1%
Gross Margin
14.2%
Net Margin
17.5%
ROIC
10.0%
WACC
ROIC − WACC Spread: +7.5%— Positive value creation spread.
+8.6%
Revenue Growth (YoY)
+20.3%
Earnings Growth (YoY)
4.5B
Free Cash Flow
43%
FCF Payout Ratio

✅ Conservative payout — room for dividend increases.

DuPont Analysis — ROE Decomposition

Breaking down Return on Equity to see how the company generates its ROE — efficiency, margins, or leverage.

14.2%
Net Profit Margin
NI ÷ Revenue
×
0.74x
Asset Turnover
Revenue ÷ Assets
×
2.70x
Equity Multiplier
Assets ÷ Equity
=
28.4%
Return on Equity
Balanced ROE composition across margins, turnover, and leverage.

Balance Sheet Health

1.70x
Debt / Equity
1.56x
Current Ratio
73.3x
Interest Coverage
0.4x
Net Debt / EBITDA
3.64%
FCF Yield
7.1B
EBITDA

Earnings Surprise History

Q4
✓ Beat
Est: $0.55
Act: $0.61
+11.1%
Q3
✓ Beat
Est: $0.65
Act: $0.70
+8.6%
Q2
✗ Miss
Est: $0.70
Act: $0.69
-1.4%
Q1
✓ Beat
Est: $0.70
Act: $0.73
+3.9%

EPS estimates vs actuals for the most recent reported quarters. Source: yfinance.

Underwater (Drawdown from Peak)

How far below the all-time high the price has been over time. Deeper = more pain for holders.

Loading drawdown chart...

Rolling 60-Day Beta vs S&P 500 (VOO)

How the stock's sensitivity to market moves changes over time. β > 1 = more volatile than the market.

Loading beta chart...
Rolling Beta Market (β = 1.0)

Fundamentals

25.7
Forward P/E
PEG Ratio
9.43
Price/Book
3M
Avg Volume
$72.12
52W High
$37.25
52W Low
52W Range Position

ABBN.SW Capital Efficiency

How efficiently does ABBN.SW convert operating profits into free cash? The FCF Conversion ratio measures the gap between accounting earnings and real cash generation.

Free Cash Flow
$4.5B
EBITDA
$7.1B
FCF Conversion
63%
Reinvestment Rate
37%
63% of EBITDA → Free Cash
0% (cash burn)25% (low)50% (efficient)100% (pure cash)
ROIC
17.5%
ROIC − WACC Spread
7.5%

ABBN.SW converts 63% of its EBITDA into free cash flow, an exceptional conversion rate indicating an asset-light business model with minimal capital reinvestment drag. The positive ROIC-WACC spread of 7.5% confirms that reinvested capital creates shareholder value.

Capital efficiency = Free Cash Flow ÷ EBITDA. Reinvestment = (EBITDA − FCF) ÷ EBITDA. Metrics from latest annual filings. Not investment advice.

Compare ABBN.SW to Peers

Quant metrics computed deterministically from financial statements and price data. Updated: N/A.

SecuritiesDB provides programmatic data aggregation for informational purposes only. None of the metrics, summaries, or algorithmic flags constitute a recommendation to buy or sell any security.